Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR-mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study

Authors

Natasha Leighl

Published

June 10, 2024

Abstract

Phase III studies of intravenous amivantamab demonstrated efficacy across epidermal growth factor receptor (

Supporters

Support the authors with ResearchCoin

Journal

Journal of Clinical Oncology

Topics

Pulmonary And Respiratory Medicine

DOI

10.1200/jco.24.01001

Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR-mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study

Authors

Natasha Leighl

Published

June 10, 2024

Abstract

Phase III studies of intravenous amivantamab demonstrated efficacy across epidermal growth factor receptor (

Supporters

Support the authors with ResearchCoin

Journal

Journal of Clinical Oncology

Topics

Pulmonary And Respiratory Medicine

DOI

10.1200/jco.24.01001

Paper

Paper

Paper

Paper

Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR-mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study

Abstract

Supporters

Journal

Topics

DOI

Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR-mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study

Abstract

Supporters

Journal

Topics

DOI